Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 4.17% is 635% above its 5-year average of -0.78%, near the high end of its 5-year range (-3.42%–4.17%).
704.35% above its 12-month average of -0.69%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 1.53%.
RETURN ON ASSETS (ROA)
4.17%
RETURN ON ASSETS (ROA) AVG TTM
-0.69%
RETURN ON ASSETS (ROA) AVG 3Y
-1.80%
RETURN ON ASSETS (ROA) AVG 5Y
-0.78%
RETURN ON ASSETS (ROA) AVG 10Y
2.52%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+704.35%
CURRENT VS 3Y AVG
+331.02%
CURRENT VS 5Y AVG
+634.62%
CURRENT VS 10Y AVG
+65.24%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.22%
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
+114.78%
vs the sector median at left
Amneal Pharmaceuticals, Inc.
Market Cap
$6.52B
Return on Assets (ROA)
4.17%
TTM Avg
-0.69%
3Y Avg
-1.80%
5Y Avg
-0.78%
Market Cap
$6.53B
Return on Assets (ROA)
11.40%
TTM Avg
13.13%
3Y Avg
12.04%
5Y Avg
6.40%
Market Cap
$6.66B
Return on Assets (ROA)
-3.91%
TTM Avg
11.88%
3Y Avg
0.12%
5Y Avg
-6.73%
Market Cap
$6.72B
Return on Assets (ROA)
17.41%
TTM Avg
17.14%
3Y Avg
16.98%
5Y Avg
18.36%
Market Cap
$6.24B
Return on Assets (ROA)
-31.62%
TTM Avg
-41.85%
3Y Avg
-50.05%
5Y Avg
-46.34%
Market Cap
$6.84B
Return on Assets (ROA)
-63.13%
TTM Avg
-53.05%
3Y Avg
-49.25%
5Y Avg
-42.24%
Market Cap
$6.11B
Return on Assets (ROA)
9.02%
TTM Avg
3.77%
3Y Avg
2.45%
5Y Avg
2.33%
Market Cap
$7.03B
Return on Assets (ROA)
1.51%
TTM Avg
13.71%
3Y Avg
9.00%
5Y Avg
4.65%
Market Cap
$6.01B
Return on Assets (ROA)
-20.67%
TTM Avg
-16.00%
3Y Avg
-20.09%
5Y Avg
-20.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.52B | 4.17% | -0.69% | -1.80% | -0.78% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.53B | 11.40% | 13.13% | 12.04% | 6.40% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.66B | -3.91% | 11.88% | 0.12% | -6.73% |
| Chemed Corporation (CHE)vs › | $6.72B | 17.41% | 17.14% | 16.98% | 18.36% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $6.24B | -31.62% | -41.85% | -50.05% | -46.34% |
| Immunovant, Inc. (IMVT)vs › | $6.84B | -63.13% | -53.05% | -49.25% | -42.24% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.11B | 9.02% | 3.77% | 2.45% | 2.33% |
| Alkermes plc (ALKS)vs › | $7.03B | 1.51% | 13.71% | 9.00% | 4.65% |
| CG Oncology Inc. (CGON)vs › | $6.01B | -20.67% | -16.00% | -20.09% | -20.45% |
| GRAIL Inc. (GRAL)vs › | $7.07B | -13.77% | -40.95% | -52.61% | -44.58% |
ROA
4.2%
ROE
476.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 1.96% |
| 2024-12-31 | -3.34% |
| 2023-12-31 | -2.42% |
| 2022-12-31 | -3.42% |
| 2021-12-31 | 0.27% |
| 2020-12-31 | 2.27% |
| 2019-12-31 | -9.87% |
| 2018-12-31 | -3.90% |
| 2017-12-31 | 12.49% |
| 2016-12-31 | 17.01% |
| 2015-12-31 | 16.71% |
| 2014-12-31 | 0.00% |
